01Oct 2024
Finerenone Reduces Cardiovascular Risk in HF Patients Regardless of SGLT2i Use

Finerenone Reduces Cardiovascular Risk in HF Patients Regardless of SGLT2i Use

The FINEARTS-HF trial demonstrated that finerenone reduced the risk of worsening heart failure events and cardiovascular death in patients with heart failure and left ventricular ejection fraction ≥40%, regardless of concomitant sodium-glucose co-transporter-2 inhibitor (SGLT2i) use. Among 6,001 participants, 13.6% were treated with an SGLT2i at baseline. Finerenone showed similar benefits in both groups, with rate ratios of 0.83 (95% CI: 0.60 to 1.16) for SGLT2i users and 0.85 (95% CI: 0.74 to 0.98) for non-users (Pinteraction=0.76). During the trial, fewer participants initiated SGLT2i in the finerenone group compared to placebo (17.7% vs. 20.1%). Time-updated analyses confirmed that SGLT2i use did not alter finerenone’s effects. These results suggest that finerenone provides cardiovascular protection independent of SGLT2i use, and combined therapy may offer enhanced benefits.

  • #cardiology

Like

Save

Share